Mometasone Furoate; Olopatadine Hydrochloride Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 1 pharmaceutical company such as GLENMARK SPECLT. It is marketed under 1 brand name, including RYALTRIS. Available in 1 different strength, such as 0.025MG/SPRAY;0.665MG/SPRAY, and administered through 1 route including SPRAY, METERED;NASAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"81415","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US9937189B2","cleaned_patent_number":"9937189","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2018-04-10","legal_status":"Granted"} US9937189B2 Formulation 10 Apr, 2018 Granted 04 Sep, 2034
{"application_id":"81417","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10376526B2","cleaned_patent_number":"10376526","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2019-08-13","legal_status":"Patented case"} US10376526B2 Formulation 13 Aug, 2019 Patented case 04 Sep, 2034
{"application_id":"81418","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10517880B2","cleaned_patent_number":"10517880","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2019-12-31","legal_status":"Granted"} US10517880B2 Formulation 31 Dec, 2019 Granted 04 Sep, 2034
{"application_id":"81419","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10548907B2","cleaned_patent_number":"10548907","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2020-02-04","legal_status":"Granted"} US10548907B2 04 Feb, 2020 Granted 04 Sep, 2034
{"application_id":"81420","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10561672B2","cleaned_patent_number":"10561672","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2020-02-18","legal_status":"Granted"} US10561672B2 Formulation 18 Feb, 2020 Granted 04 Sep, 2034
{"application_id":"81421","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10646500B2","cleaned_patent_number":"10646500","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2020-05-12","legal_status":"Patented case"} US10646500B2 12 May, 2020 Patented case 04 Sep, 2034
{"application_id":"81423","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10758550B2","cleaned_patent_number":"10758550","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2020-09-01","legal_status":"Granted"} US10758550B2 01 Sep, 2020 Granted 04 Sep, 2034
{"application_id":"81347","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10765686B2","cleaned_patent_number":"10765686","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2020-09-08","legal_status":"Patented case"} US10765686B2 08 Sep, 2020 Patented case 04 Sep, 2034
{"application_id":"81424","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US11400101B2","cleaned_patent_number":"11400101","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2022-08-02","legal_status":"Granted"} US11400101B2 02 Aug, 2022 Granted 04 Sep, 2034
{"application_id":"81414","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US9750754B2","cleaned_patent_number":"9750754","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2017-09-05","legal_status":"Patented case"} US9750754B2 Formulation 05 Sep, 2017 Patented case 04 Sep, 2034
{"application_id":"81416","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US10016443B2","cleaned_patent_number":"10016443","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2018-07-10","legal_status":"Patented case"} US10016443B2 10 Jul, 2018 Patented case 04 Sep, 2034
{"application_id":"116137","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US2022387452A1","cleaned_patent_number":"12064442","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2024-08-20","legal_status":"Pending"} US12064442B2 20 Aug, 2024 Pending 04 Sep, 2034
{"application_id":"81412","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US9078923B2","cleaned_patent_number":"9078923","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2015-07-14","legal_status":"Patented case"} US9078923B2 Formulation 14 Jul, 2015 Patented case 04 Sep, 2034
{"application_id":"81413","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US9370483B2","cleaned_patent_number":"9370483","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-04","publication_date":"2016-06-21","legal_status":"Granted"} US9370483B2 Formulation 21 Jun, 2016 Granted 04 Sep, 2034
{"application_id":"81426","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US11679210B2","cleaned_patent_number":"11679210","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-09-03","publication_date":"2023-06-20","legal_status":"Granted"} US11679210B2 Formulation 20 Jun, 2023 Granted 03 Sep, 2038
{"application_id":"116138","ingredient":"MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE","trade_name":"RYALTRIS","family_id":"880982609fe447ee8054","publication_number":"US2023285689A1","cleaned_patent_number":"12303635","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-04-08","publication_date":"2025-05-20","legal_status":"Pending"} US12303635B2 Molecular Formulation 20 May, 2025 Pending 08 Apr, 2039

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Mometasone Furoate; Olopatadine Hydrochloride

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.